These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 37506762)

  • 61. A CADD-alog of strategies in pharma.
    Warr WA
    J Comput Aided Mol Des; 2017 Mar; 31(3):245-247. PubMed ID: 28315993
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Partnership between small biotech and big pharma.
    Wiederrecht GJ; Hill RG; Beer MS
    IDrugs; 2006 Aug; 9(8):560-4. PubMed ID: 16871465
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Tip of the Iceberg? Country- and Company-Level Analysis of Drug Company Payments for Research and Development in Europe.
    Ozieranski P; Martinon L; Jachiet PA; Mulinari S
    Int J Health Policy Manag; 2022 Dec; 11(12):2842-2859. PubMed ID: 35297231
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Tracking 20 years of compound-to-target output from literature and patents.
    Southan C; Varkonyi P; Boppana K; Jagarlapudi SA; Muresan S
    PLoS One; 2013; 8(10):e77142. PubMed ID: 24204758
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The genetics of a pharma merger.
    Sanseau P; Chabot-Fletcher M; Browne MJ
    Drug Discov Today; 2009 Apr; 14(7-8):334-6. PubMed ID: 19121408
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Sharing of clinical trial data and results reporting practices among large pharmaceutical companies: cross sectional descriptive study and pilot of a tool to improve company practices.
    Miller J; Ross JS; Wilenzick M; Mello MM
    BMJ; 2019 Jul; 366():l4217. PubMed ID: 31292127
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Agricultural R&D, technology and productivity.
    Piesse J; Thirtle C
    Philos Trans R Soc Lond B Biol Sci; 2010 Sep; 365(1554):3035-47. PubMed ID: 20713401
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Profitability of Large Pharmaceutical Companies Compared With Other Large Public Companies.
    Ledley FD; McCoy SS; Vaughan G; Cleary EG
    JAMA; 2020 Mar; 323(9):834-843. PubMed ID: 32125401
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Are the economics of pharmaceutical research and development changing?: productivity, patents and political pressures.
    Grabowski H
    Pharmacoeconomics; 2004; 22(2 Suppl 2):15-24. PubMed ID: 15660474
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Should the United States government regulate prescription prices? A critical review.
    Patterson JA; Carroll NV
    Res Social Adm Pharm; 2020 May; 16(5):717-723. PubMed ID: 31248779
    [TBL] [Abstract][Full Text] [Related]  

  • 71. What do pharmaceutical industry professionals in Europe believe about involving patients and the public in research and development of medicines? A qualitative interview study.
    Parsons S; Starling B; Mullan-Jensen C; Tham SG; Warner K; Wever K
    BMJ Open; 2016 Jan; 6(1):e008928. PubMed ID: 26743701
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Systematic risk identification and assessment using a new risk map in pharmaceutical R&D.
    Schuhmacher A; Brieke C; Gassmann O; Hinder M; Hartl D
    Drug Discov Today; 2021 Dec; 26(12):2786-2793. PubMed ID: 34229082
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Evolving patterns in a collaboration network of global R&D on monoclonal antibodies.
    Kong X; Wan JB; Hu H; Su S; Hu Y
    MAbs; 2017 Oct; 9(7):1041-1051. PubMed ID: 28737444
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Powered by Open Innovation: Opportunities and Challenges in the Pharma Sector.
    Martinez-Grau MA; Alvim-Gaston M
    Pharmaceut Med; 2019 Jun; 33(3):193-198. PubMed ID: 31933287
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Open innovation in early drug discovery: roadmaps and roadblocks.
    Reichman M; Simpson PB
    Drug Discov Today; 2016 May; 21(5):779-88. PubMed ID: 26743597
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Discovery of innovative therapeutics: today's realities and tomorrow's vision. 2. Pharma's challenges and their commitment to innovation.
    Abou-Gharbia M; Childers WE
    J Med Chem; 2014 Jul; 57(13):5525-53. PubMed ID: 24428137
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Recent drug approvals from the US FDA and EMEA: what the future holds.
    Pevarello P
    Future Med Chem; 2009 Apr; 1(1):35-48. PubMed ID: 21426069
    [TBL] [Abstract][Full Text] [Related]  

  • 78. How should we support pharmaceutical innovation?
    Grootendorst P
    Expert Rev Pharmacoecon Outcomes Res; 2009 Aug; 9(4):313-20. PubMed ID: 19670991
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Indian pharma enters the global arena.
    Singh S
    Cell; 2007 Mar; 128(5):811-4. PubMed ID: 17350563
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Comparison of Research Spending on New Drug Approvals by the National Institutes of Health vs the Pharmaceutical Industry, 2010-2019.
    Galkina Cleary E; Jackson MJ; Zhou EW; Ledley FD
    JAMA Health Forum; 2023 Apr; 4(4):e230511. PubMed ID: 37115539
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.